Navigation Links
Study targets treatment for serious ACE inhibitor side effect
Date:4/28/2011

DETROIT A new Henry Ford Hospital study takes a closer look at one of the lesser known, but potential most serious side-effects of ACE inhibitor use facial, tongue and airway swelling and identifies a successful and less invasive course of treatment.

Using a treatment protocol developed by Henry Ford, patients' symptoms were quickly diagnosed and promptly treated to reduce swelling, resulting in no tracheotomies to open the airway or reported deaths, says study author Samer Al-Khudari, M.D.

"This side-effect is rare, but when it happens, it can be anxiety-provoking for both patients and physicians," says Dr. Al-Khudari, a member of the Department of Otolaryngology-Head & Neck Surgery at Henry Ford.

"Our goal was to really take a closer look at the treatment options available and develop a better standard of care for not just otolaryngologist, but all health care providers to follow."

The study will presented April 30 at 114th Annual Meeting of the Triological Society, part of the Combined Otolaryngology Spring Meetings in Chicago.

ACE inhibitors are a popular class of drugs most often prescribed to treat high blood pressure, congestive heart failure and kidney disease, as well as prevent stroke.

While they are well-tolerated by most patients, there are some side effects including angiodema, swelling that occurs in areas of the head and neck (floor of mouth, tongue, lips, throat) and can lead to airway obstruction.

Patients most commonly come into the emergency department experiencing difficulty swallowing, shortness of breath and voice changes.

ACE inhibitor induced angiodema (AIIA) tends to be more common among African Americans.

The study included 40 patients who received care at Henry Ford Hospital over a one-year period. The majority of patients (92%) were African American, and most were taking an ACE inhibitor called Lisinopril.

Treatment for all patients at Henry Ford included IV corticosteroids and antihistamines. On average, medical therapy was initiated by otolaryngology services about one hour after the initial evaluation in the emergency department.

All patients underwent a physical examination and laryngoscopy, which uses a flexible viewing tube to evaluate the back of the throat, including the voice box. Floor of mouth swelling was present in 50% of patients, and massive tongue swelling was found in 11.6%.

About half of the patients were admitted to the intensive care unit, while six required intubation and 14 were monitored and discharged from the ER. None of the patients needed emergency tracheotomy or cricothyrotomy for airway control.

Throughout the course of treatment, inpatients were evaluated at least twice a day by the otolaryngology service, and repeat flexible laryngoscopy was performed based on symptoms. Patients were discharged with or without a tapered steroid dose and scheduled for outpatient follow-up.

For most patients, AIIA was resolved in 27 hours.

"If a patient taking an ACE inhibitor notices intermittent swelling in the mouth, lips, face, the medication may very well be the culprit. When this type of swelling occurs, we recommend that patients contact their health care providers immediately and not wait for symptoms to worsen," says Dr. Khudari.

Regardless, Dr. Khudari says it's very important for patients to note that the benefits of ACE inhibitors greatly outweigh the potential risks.


'/>"/>

Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. JAMA study reports on fatty liver disease in children and teens
2. Armadillos Give Leprosy to Humans in Southern U.S.: Study
3. Study Highlights Arthritis Toll on Quality of Life
4. Morning Heart Attacks Cause More Damage, Study Finds
5. Higher Oxygen Levels Improve Preemie Survival: Study
6. Baycrest and NHL Alumni partner on brain health study
7. Removing Ovaries During Hysterectomy Wont Raise Other Health Risks: Study
8. University of Houston wins NIH grant for vaccine study
9. When Docs Own MRIs, Back Pain Scans Increase: Study
10. Evidence-Based Heart Attack Care Reduces Deaths: Study
11. Study: Resiniferatoxin may increase sepsis-related mortality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that provides ... employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow job ...
(Date:8/21/2017)... ... August 21, 2017 , ... Los Angeles ... surgery fellows for academic year 2017-2018, Christina M. Busuito, M.D. and Lukasz Swistun, ... residency in Plastic and Reconstructive Surgery. The candidate will have the opportunity ...
(Date:8/21/2017)... ... August 21, 2017 , ... Five chefs from local senior ... Alzheimer’s Family Center. , Guests will be able to vote for their favorite ... Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita Crisp, Greek ...
(Date:8/21/2017)... ... ... The experts have spoken. Prolonged sitting and standing are a no-no for optimal ... way these days? FlexiSpot, one of the fastest-growing manufacturers of ergonomic office solutions, has ... Pro™– the world’s first sit-stand-cycle desk to backers worldwide. , The Launch , Part ...
(Date:8/21/2017)... San Diego, CA (PRWEB) , ... August 21, 2017 , ... ... Membership ( MAM ) health care reform plan, has announced his candidacy for the ... the American Dream and shared in America’s Promise. Coming to this country at age ...
Breaking Medicine News(10 mins):
(Date:8/11/2017)... CAESAREA, Israel , Aug. 11, 2017 ... company with mobile health and big data solutions, today ... results on Monday, August 14 and host a conference ... second quarter 2017 operating and financial results and its ... call will be hosted by Erez Raphael , ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of ... 27, 2017 to stockholders of record as of the close ... are subject to approval of the Board of Directors and ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
Breaking Medicine Technology: